Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P20366 (
substance P
)
21,176
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
GPR88
, an orphan G protein-coupled receptor, was designated Strg/
GPR88
for
striatum-specific G protein-coupled receptor
(K. Mizushima et al. (2000)Genomics, 69, 314-321). In this study, we focused on striatal
GPR88
protein localization using a polyclonal antibody. We established that the distribution of immunoreactivity in rat brain matched that of
GPR88
transcripts and provided evidence for its exclusive neuronal expression.
GPR88
protein is abundant throughout the striatum of rat and primate, with expression limited to the two subsets of striatal projection medium spiny neurons (MSNs) expressing
preprotachykinin
-
substance P
or preproenkephalin mRNAs. Ultrastructural immunolabelling revealed the
GPR88
concentration at post-synaptic sites along the somatodendritic compartments of MSNs, with pronounced preference for dendrites and dendritic spines. The
GPR88
-rich expression, in both striatal output pathways, designates this receptor as a potential therapeutic target for diseases involving dysfunction of the basal ganglia, such as Parkinson's disease. Hence, we investigated changes of
GPR88
expression in a model of Parkinson's disease (unilateral 6-hydroxydopamine-lesioned rats) following repeated L-DOPA treatment. In dopamine-depleted striatum,
GPR88
expression was differentially regulated, i.e. decreased in striatopallidal and increased in striatonigral MSNs. L-DOPA treatment led to a normalization of
GPR88
levels through dopamine D1 and D2 receptor-mediated mechanisms in striatopallidal and striatonigral MSNs, respectively. Moreover, the removal of corticostriatal inputs, by ibotenate infusion, downregulated
GPR88
in striatopallidal MSNs. These findings provide the first evidence that
GPR88
is confined to striatal MSNs and indicate that L-DOPA-mediated behavioural effects in hemiparkinsonian rats may involve normalization of striatal
GPR88
levels probably through dopamine receptor-mediated mechanisms and modulations of corticostriatal pathway activity.
...
PMID:Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents. 1965 74